Chi­na opens the door for biotech in­vestors in Hong Kong to buy Shang­hai stocks, and vice ver­sa

When Shang­hai’s STAR board be­gan open­ing its doors to biotech, it was con­sid­ered not just a ri­val to Nas­daq but al­so the stock ex­change in Hong Kong. Those per­cep­tions may take an am­i­ca­ble turn as Chi­na ex­pands a mu­tu­al ac­cess pro­gram with the city.

The changes mean in­vestors in main­land Chi­na will be able to own Hong Kong biotech chap­ter stocks, while those in Hong Kong — a much more in­ter­na­tion­al­ly con­nect­ed group — would have ac­cess to those list­ed on STAR. In ef­fect, it turns the Shang­hai mar­ket in­to a glob­al­ly ac­ces­si­ble ex­change overnight while al­so broad­en­ing a key source of rev­enue for HKEX.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.